Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Hykin

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
JAMA Ophthalmology|August 30, 2019
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical TrialPhilip Hykin, A Toby Prevost, Joana C Vasconcelos, et al.
The British Journal of Ophthalmology|April 1, 2016
Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA studyFrank G Holz, Ramin Tadayoni, Stephen Beatty, et al.
BMJ (Clinical Research Ed.)|June 12, 2010
Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked studyAdnan Tufail, Praveen J Patel, Catherine Egan, et al.
The British Journal of Ophthalmology|September 7, 2014
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degenerationFrank G Holz, Ramin Tadayoni, Stephen Beatty, et al.
Ophthalmic Research|November 11, 2016
Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component AnalysisFrank G Holz, Ramin Tadayoni, Stephen Beatty, et al.
BMJ Open|September 16, 2015
Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trialSobha Sivaprasad, A Toby Prevost, James Bainbridge, et al.
Pharmacoeconomics|April 26, 2021
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO StudyBecky Pennington, Abualbishr Alshreef, Laura Flight, et al.
Pharmacoeconomics|June 20, 2021
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO StudyBecky Pennington, Abualbishr Alshreef, Laura Flight, et al.
Health Technology Assessment (Winchester, England)|June 16, 2021
Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCTPhilip Hykin, A Toby Prevost, Sobha Sivaprasad, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
JAMA Ophthalmology|August 30, 2019
Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical TrialPhilip Hykin, A Toby Prevost, Joana C Vasconcelos, et al.
The British Journal of Ophthalmology|April 1, 2016
Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA studyFrank G Holz, Ramin Tadayoni, Stephen Beatty, et al.
BMJ (Clinical Research Ed.)|June 12, 2010
Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked studyAdnan Tufail, Praveen J Patel, Catherine Egan, et al.
The British Journal of Ophthalmology|September 7, 2014
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degenerationFrank G Holz, Ramin Tadayoni, Stephen Beatty, et al.
Ophthalmic Research|November 11, 2016
Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component AnalysisFrank G Holz, Ramin Tadayoni, Stephen Beatty, et al.
BMJ Open|September 16, 2015
Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): a multicentre phase IIb randomised active-controlled clinical trialSobha Sivaprasad, A Toby Prevost, James Bainbridge, et al.
Pharmacoeconomics|April 26, 2021
Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO StudyBecky Pennington, Abualbishr Alshreef, Laura Flight, et al.
Pharmacoeconomics|June 20, 2021
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO StudyBecky Pennington, Abualbishr Alshreef, Laura Flight, et al.
Health Technology Assessment (Winchester, England)|June 16, 2021
Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCTPhilip Hykin, A Toby Prevost, Sobha Sivaprasad, et al.
Pageof 4